TELA Bio, Inc. (TELA) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, primarily through its OviTex (hernia repair) and OviTex PRS (plastic and reconstructive surgery) product portfolios. The company operates as a single reportable segment and relies on an exclusive contract manufacturer, Aroa Biosurgery Ltd., for its core products.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $19.1 million | $18.5 million |
| Gross Profit | $12.5 million | $12.5 million |
| Gross Margin | 66% | 68% |
| Net Loss | $(12.3) million | $(11.3) million |
| Diluted EPS | $(0.21) | $(0.25) |
| Cash and Equivalents | $39.5 million | $42.8 million |
| Long-Term Debt | $55.9 million | $55.7 million |
| Operating Cash Flow | $(11.2) million | $(9.7) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 3% year-over-year, driven by a 16% increase in OviTex unit sales volume and growth in international sales. This was partially offset by a 3% decline in OviTex PRS unit sales and price mix headwinds in the U.S.
- Margin Compression: Gross margin decreased from 68% to 66% due to a higher charge for excess and obsolete inventory ($0.9 million in Q1 2026 vs. $0.6 million in Q1 2025).
- Expense Management: Sales and marketing expenses remained flat, while R&D expenses decreased 8% due to lower study costs. General and administrative expenses increased 9% due to higher professional fees.
- Interest Expense: Interest expense surged 68% to $2.1 million, reflecting the higher borrowing base and interest rate associated with the new Perceptive Term Loan Facility entered into in November 2025.
- Liquidity: Cash and cash equivalents decreased by $11.3 million during the quarter, primarily due to operating losses and inventory build-up.
Outlook, Risks, and Management Commentary
- Liquidity Position: Management believes existing cash resources ($39.5 million) are sufficient to fund operations for at least the next 12 months. The company maintains a $60 million term loan with Perceptive Credit Holdings, maturing in November 2030, with an additional $10 million delayed draw option available subject to revenue thresholds.
- Debt Covenants: The Perceptive Credit Agreement requires the company to maintain minimum liquidity of $5.0 million and meet specific revenue thresholds. Failure to meet these could trigger an Event of Default.
- Macroeconomic Risks: The company faces risks from a 10% U.S. tariff on imports from New Zealand (where products are manufactured), which is shared equally with the manufacturer but may impact pricing and demand. Other risks include supply chain disruptions for critical surgical supplies and potential hospital financial strain.
- Product Pipeline: The company continues to invest in R&D for new product configurations and is pursuing FDA approval for OviTex PRS in implant-based breast reconstruction.
Investor Verification Checklist
- Debt Covenants: Verify current revenue levels against the specific thresholds required by the Perceptive Credit Agreement to avoid default.
- Inventory Valuation: Review the methodology and magnitude of the excess and obsolete inventory charge ($0.9 million) and its impact on future margins.
- Tariff Impact: Assess the actual pass-through of the 10% New Zealand tariff to customers and its effect on unit sales volume.
- Cash Burn Rate: Monitor the quarterly cash burn rate relative to the $39.5 million cash balance to confirm the 12-month runway assertion.
- Unit Sales Trends: Investigate the reasons behind the 3% decline in OviTex PRS unit sales despite overall revenue growth.